Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Len + pembro metastatic clear cell renal cell carcinoma

Chung Han-Lee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, gives an overview of data coming from the phase II trial (NCT02501096) of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).